What changed
$SYK — BUY 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $6.0B | EPS $2.60 vs $2.98 🔴 | Margin 25.7%
💡 Consensus expected a beat based on historical execution, leading to a negative surprise and reset of short-term expectations. The variant view is that the miss was idiosyncratic and transient (e.g., supply chain, timing), and the maintained guidance implies confidence in recovery, while the market has priced in a more persistent slowdown.
📉 Reward/risk: 1.94:1
🏢 Business Quality: 8/10 - Stryker is a leading medtech company with dominant positions in orthopedics, medical-surgical, and neurotechnology markets, benefiting from an aging population, high recurring revenue, and strong competitive moats. Returns on capital are robust, and innovation pipeline is solid.
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/SYK0617